CDK4/6抑制剂联合内分泌治疗晚期乳腺癌

内分泌治疗因疗效显著并具有安全性,是激素受体阳性(HR+)晚期乳腺癌患者的主要治疗方法。近年来内分泌领域发展迅速,如何延迟或逆转内分泌耐药及内分泌治疗新药物成为临床研究关注的焦点。研究发现,内分泌治疗耐药可能与CDK-RB-E2F通路有关,针对该通路的细胞周期蛋白依赖性激酶(CDK)4/6抑制剂可显著延缓HR+晚期乳腺癌患者内分泌耐药。CDK4/6抑制剂与内分泌药物联合使用,可提高HR+晚期乳腺癌患者的治疗客观缓解率,并可显著改善无进展生存期(PFS)。现就CDK4/6抑制剂的作用机制、药物有效性和安全性及相关临床试验做一综述。

Research progress of CDK4/6 inhibitors combined with endocrine therapy for advanced breast cancer

Endocrine therapy is the main treatment method for patients with hormone receptor positive(HR+)advanced breast cancer due to its remarkable curative effect and safety.In recent years,the field of endocrinology has developed rapidly.How to delay or reverse endocrine resistance and new endocrine therapy drugs have become the focus of clinical research.Studies have found that endocrine therapy resistance may be related to the CDK-RB-E2F pathway.It has been found that endocrine therapy resistance may be related to the CDK-RB-E2F pathway.Cyclin-dependent kinase(CDK)4/6 inhibitors targeting this pathway can significantly delay endocrine resistance in patients with HR+ advanced breast cancer.The combined use of CDK4/6 inhibitors and endocrine drugs can improve the objective response rate of patients with HR+ advanced breast cancer,and can significantly improve progression-free survival(PFS).This article reviews the mechanism of action,drug effectiveness and safety of CDK4/6 inhibitors,and related clinical trials.